-
Mashup Score: 4
A meta-analysis of three trials assessing the use of SGLT2 inhibitors for inpatients with COVID-19 showed the drug class did not reduce risk for death or other outcomes compared with usual care or placebo, but was safe.“The fundamental pathobiology of COVID-19 infection and organ damage includes many pathophysiologic properties that, at least theoretically, could be impacted in a favorable
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 2GLP-1 Agonists May Reduce Adverse CV Event Risk Regardless of SGLT2 Inhibitor Use in Patients with TD2, CVD: Post Hoc Analysis - 2 year(s) ago
In patients with type 2 Diabetes (T2D) and cardiovascular disease, treatment with a GLP-1 receptor agonist (GLP-1 RA) reduces the risk of adverse cardiovascular events independently of background sodi
Source: www.crtonline.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In patients with type 2 #Diabetes & #CVD, treatment with GLP-1 RA decreases the risk of adverse CV events independently of background #SGLT2 use, according to findings in #JACC. https://t.co/Rp3tHPZi9t @CRT_meeting
-
-
Mashup Score: 9
Both SGLT2 inhibitors and GLP-1 receptor agonists were associated with reduced risk of MACE compared with DPP-4 inhibitors or sulfonylureas. DPP-4 inhibitors were associated with reduced risk of MACE compared with sulfonylureas. There was no statistically significant difference in risk of MACE between SGLT2 inhibitors and GLP-1 receptor agonists. The results provide evidence of the real-world comparative effectiveness of the four most commonly used second-line antihyperglycaemics and could guide choice of antihyperglycaemic therapy.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
Comparative effectiveness of #SGLT2 inhibitors, #GLP-1 receptor agonists, #DPP-4 inhibitors, and #sulfonylureas on risk of major adverse #cardiovascular events: emulation of a randomised target trial using electronic health records https://t.co/kgPDb2tPYn #T2D #CVD
-
-
Mashup Score: 16SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy - 2 year(s) ago
Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown. Methods We applied empagliflozin treatment to lupus-prone MRL/ lpr mice to explore the renal protective potential of SGLT2 inhibitors. An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms. Results In MRL/ lpr mice treated with empagliflozin, the levels of mouse anti-dsDNA IgG-specific antibodies, serum creatinine and proteinuria were markedly decreased. For renal pathology assessment, both the glomerular and tubulointerstitial damages were lessened by administration of empagliflozin. The levels of SGLT2 expression were increased and colocalised with decreased synaptopodin in the renal biopsy samples
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet-
Empagliflozin treatment to #lupus prone MRL/lpr mice to explore renal protective potential of #SGLT2 inhibitors. The SGLT2 inhibitor empagliflozin alleviated #podocyte injury by attenuating inflammation & enhanced autophagy by reducing mTORC1 activity. https://t.co/9EJDG0lOph https://t.co/zlaNSW5MJu
-
-
Mashup Score: 2The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer: - 2 year(s) ago
Abstract Background Sodium glucose cotransporter-2 inhibitors (SGLT2is) are hypothesized to reduce the risk of anthracycline-associated cardiotoxicity. Objectives This study sought to determine the…
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet-
Really nice thought-provoking work by @dineshpmcc1 & colleagues in @JACCJournals:#CardioOnc examining #SGLT2 inhibitors & cardioprotection in #anthracycline treated patients. 🤔Good rationale for randomized trials. Congrats! https://t.co/T40J1W9YdU https://t.co/5yNtd0iT2S
-
-
Mashup Score: 2Top news June 2023: FDA approvals, updates from NLA and more - 2 year(s) ago
Healio | Cardiology Today has compiled a list of the top headlines in cardiology of June 2023.Readers were most interested in the FDA approvals of colchicine 0.5 mg, IV ferric carboxymaltose and mavacamten for various CV indications; updates from the National Lipid Association Scientific Sessions and Heart in Diabetes CME Conference; and more.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A #JACC study found that #SGLT2 inhibitors reduce the risk of CV death and #HeartFailure events in patients with heart failure, #diabetes and chronic kidney disease. https://t.co/66QuRG6Pys @CardiologyToday
-
-
Mashup Score: 0SGLT2 Inhibitors May Improve CV Outcomes in Select Populations, Meta-Analysis Suggests - 2 year(s) ago
A new meta-analysis suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors can improve clinical outcomes in patients with heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidne
Categories: Cardiology News and Journals, Latest HeadlinesTweet-
A new meta-analysis in #JACC found that #SGLT2 can improve CV outcomes in patients with #HeartFailure, #diabetes and chronic kidney disease. https://t.co/4bK3OFKfJw @CRT_meeting
-
-
Mashup Score: 1Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations - 2 year(s) ago
SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.The researchers conducted a meta-analysis of 13 trials of SGLT2 inhibitors vs. placebo in 90,413 patients with HF, type 2 diabetes and/or chronic kidney disease (CKD).
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to a meta-analysis in #JACC, #SGLT2 inhibitors decrease the risk of CV death and #HeartFailure hospitalization in high-risk patients. @CardiologyToday covers the findings here: https://t.co/TaQXfHSgve
-
-
Mashup Score: 1SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism - Nature Reviews Cardiology - 2 year(s) ago
In this Review, Packer summarizes the latest advances in our understanding of the mechanisms that underlie the benefits of sodium–glucose cotransporter 2 (SGLT2) inhibitors in heart failure, identifies specific pathways that are likely to mediate a direct effect of SGLT2 inhibitors on cardiomyocytes and proposes a novel conceptual framework that explains the findings from experimental studies and…
Source: NatureCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The Review #SGLT2 inhibitors: role in protective reprogramming of #cardiac nutrient transport and #metabolism by Milton Packer now Free to read for 1 month for the launch of our new Series on Cardiometabolism: https://t.co/mCNKwaEmfw
-
A meta-analysis of 3 trials of #SGLT2 inhibitors for inpatients with #COVID19 showed they did not reduce risk for death/other outcomes vs. usual care or placebo, but was safe @MkosiborodMD @InfectDisNews @MidAmericaHeart #ESCCongress #cardiotwitter https://t.co/wc5uPhkvdb